Crizanlizumab
Crizanlizumab Basic information
- Product Name:
- Crizanlizumab
- Synonyms:
-
- Crizanlizumab
- Research Grade Crizanlizumab (DHD15101)
- ADAKVEO|||SEG-101
- Research Grade Crizanlizumab
- Crizanlizumab (anti-P-Selectin)
- CAS:
- 1690318-25-2
- MW:
- 0
- Mol File:
- Mol File
Crizanlizumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Crizanlizumab Usage And Synthesis
Uses
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].
in vivo
Crizanlizumab (1 or 6 mg/kg, i.p., 3 days a week for 5 months) improving sickle cell retinopathy in four weeks old male HbSS (sickle cell disease) mice[3].
References
[1] Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020).
[2] Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. DOI:10.1056/NEJMoa1611770
[3] Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747.
CrizanlizumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com